Stable and Potent Selenomab-Drug Conjugates

Area of Science:

• Bioconjugation Chemistry
• Antibody-Drug Conjugates (ADCs)
• Protein Engineering

Background:

• Site-specific antibody-drug conjugates (ADCs) are crucial for targeted cancer therapy.
• Existing conjugation methods face limitations in efficiency and reaction conditions.
• Selenocysteine offers unique reactivity for precise molecular attachment.

Purpose of the Study:

• To engineer novel antibody-drug conjugates utilizing selenocysteine.
• To evaluate the efficiency, stability, and therapeutic potential of selenomab-drug conjugates.
• To demonstrate the broad applicability of this technology in cancer models.

Main Methods:

• Engineered monoclonal antibodies incorporating selenocysteine residues (selenomabs).
• Developed tailored conjugation chemistry for site-specific drug attachment.
• Assessed conjugate stability, potency, and selectivity in vitro and in vivo models.

Main Results:

• Achieved fast, single-step, and efficient conjugation under near physiological conditions.
• Generated highly stable selenomab-drug conjugates with demonstrated potency and selectivity.
• Showcased broad therapeutic utility in both liquid and solid malignancy models.

Conclusions:

• Selenomabs provide a robust platform for creating highly effective site-specific ADCs.
• The unique reactivity of selenocysteine enables superior conjugation chemistry.
• This approach holds significant promise for advancing cancer therapeutics.